Jazz Pharmaceuticals plc
JAZZNASDAQHealthcare● Active
$239.38
+$0.81(+0.34%)
Market Cap$15.0B
P/E Ratio—
52W High$243.32
52W Low$105
Jazz Pharmaceuticals plc (JAZZ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · JAZZ · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Cost of Revenue | $0.50B | $0.45B | $0.44B | $0.54B | $0.44B |
| Gross Profit | $3.76B | $3.62B | $3.40B | $3.12B | $2.65B |
| Gross Margin %(computed) | 88.21% | 89.05% | 88.64% | 85.23% | 85.76% |
| Operating Expenses | |||||
| R&D Expenses | $0.78B | $0.88B | $0.85B | $0.59B | $0.51B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $3.54B | $2.91B | $2.82B | $3.18B | $2.48B |
| Operating Income | $0.22B | $0.72B | $0.58B | ($0.07B) | $0.17B |
| Operating Margin %(computed) | 5.26% | 17.61% | 15.09% | -1.79% | 5.50% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.20B | $0.24B | $0.29B | $0.29B | $0.28B |
| Income Before Tax | ($0.63B) | $0.47B | $0.29B | ($0.38B) | ($0.11B) |
| Income Tax Expense | ($0.27B) | ($0.09B) | ($0.12B) | ($0.16B) | $0.22B |
| Net Income | ($0.36B) | $0.56B | $0.41B | ($0.22B) | ($0.33B) |
| Net Margin %(computed) | -8.35% | 13.77% | 10.82% | -6.12% | -10.63% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.51 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | $0.11B | $1.52B | $1.45B | $1.47B | $1.03B |
| EBITDA Margin %(computed) | 2.54% | 37.40% | 37.80% | 40.13% | 33.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Jazz Pharmaceuticals plc data
About Jazz Pharmaceuticals plc (JAZZ) Income Statement
Jazz Pharmaceuticals plc (JAZZ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, JAZZ reported revenue of $4.27B, gross profit of $3.76B (gross margin 88.21%), and net income of ($0.36B) — a net profit margin of -8.35%.
Frequently asked questions
JAZZ · 4 questionsJazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B for 2025, up 4.9% year-over-year.
JAZZ revenueJAZZ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08